<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01070628</url>
  </required_header>
  <id_info>
    <org_study_id>2939131</org_study_id>
    <nct_id>NCT01070628</nct_id>
  </id_info>
  <brief_title>Levodopa Concentration Profile With Stalevo 75/125 mg</brief_title>
  <acronym>NEWSTA</acronym>
  <official_title>Levodopa Concentration Profile After Repeated Doses of Different Stalevo® Strengths With 3.5 Hours Dosing Frequency; an Open, Randomised, Crossover, Levodopa/Carbidopa Controlled Single Centre Study in Healthy Subjects, Two Parallel Groups</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm that the dose levels and dosing frequency utilising&#xD;
      the new Stalevo strengths would result into more stable levodopa plasma levels. Therefore, it&#xD;
      is anticipated that when lower dose of Stalevo is administered after the first higher dose of&#xD;
      Stalevo, this would result in equally high levodopa maximum concentration values (Cmax) after&#xD;
      each dose throughout the day compared to Cmax after the first dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate that reduced Stalevo strengths 75 mg and 125 mg following initial 100 mg and 150 mg strengths, will not increase Cmax of levodopa compared to Stalevo or levodopa/carbidopa dosing using equal strengths during the day.</measure>
    <time_frame>2-11 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmin, AUCo-tau</measure>
    <time_frame>each subject 3 PK days between 1-6 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Stalevo (levodopa/carbidopa/entacapone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>125mg or 75mg of levodopa during treatment period 1 in groups 1 and 2 respectively.&#xD;
150mg or 100mg of levodopa during treatment period 2 in groups 1 and 2 respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sinemet (levodopa/carbidopa)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150mg or 100mg of levodopa during treatment period 3 in study groups 1 and 2 respectively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stalevo (levodopa/ carbidopa/ entacapone)</intervention_name>
    <description>150mg, 125 mg, 100mg, 75mg of levodopa q.i.d. in 3.5 h interval</description>
    <arm_group_label>Stalevo (levodopa/carbidopa/entacapone)</arm_group_label>
    <other_name>Stalevo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sinemet (levodopa/carbidopa)</intervention_name>
    <description>150 or 100 mg levodopa q.i.d. in 3.5 hr interval</description>
    <arm_group_label>Sinemet (levodopa/carbidopa)</arm_group_label>
    <other_name>Sinemet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent (IC) obtained.&#xD;
&#xD;
          -  Good general health ascertained by detailed medical history, and laboratory and&#xD;
             physical examinations.&#xD;
&#xD;
          -  Finnish speaking males or females, 18-70 years of age inclusive.&#xD;
&#xD;
          -  Normal weight defined as body mass index (BMI) 18.5-30.0 kg/m2 (inclusive) (BMI =&#xD;
             weight/height2).&#xD;
&#xD;
          -  Weight at least 50.0 kg.&#xD;
&#xD;
          -  Regular intestinal transit (no recent history of recurrent constipation, diarrhoea, or&#xD;
             other intestinal problems).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of a clinically significant cardiovascular, renal, hepatic, haematological,&#xD;
             gastrointestinal, pulmonary, metabolic-endocrine, neurological, urogenital or&#xD;
             psychiatric disease as judged by the investigator.&#xD;
&#xD;
          -  Any condition requiring regular concomitant treatment (including vitamins and herbal&#xD;
             products) or likely to need any concomitant treatment during the study. As an&#xD;
             exception, contraceptives or hormone replacement therapy are allowed.&#xD;
&#xD;
          -  Intake of any medication that could affect the outcome of the study.&#xD;
&#xD;
          -  Any clinically significant abnormal laboratory value or physical finding (including&#xD;
             electrocardiogram [ECG]) and vital signs) that may interfere with the interpretation&#xD;
             of test results or cause a health risk for the subject if he/she participates in the&#xD;
             study, as judged by the investigator.&#xD;
&#xD;
          -  Orthostatic hypotension; systolic and diastolic BP and heart rate HR after 3 minutes&#xD;
             in supine position and after 3 minutes of standing:&#xD;
&#xD;
          -  decrease of ≥ 20 mmHg for systolic BP&#xD;
&#xD;
          -  decrease of ≥ 10 mmHg for diastolic BP.&#xD;
&#xD;
          -  Strong tendency to motion sickness.&#xD;
&#xD;
          -  Known hypersensitivity to the active substance(s) or to any of the excipients of the&#xD;
             drug.&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  Females of childbearing potential if they are not using proper contraception (hormonal&#xD;
             contraception, intrauterine device (IUD) or surgical sterilization, spermicidal&#xD;
             foam/Vagitorie, condom on male partner). Double methods (mentioned above) of&#xD;
             contraception is needed during the study. (Note: women of childbearing potential with&#xD;
             no current sexual relationship can be included without contraception according to the&#xD;
             judgement of the investigator).&#xD;
&#xD;
          -  Recent or current (suspected) drug abuse or positive result in the drug abuse test.&#xD;
&#xD;
          -  Recent or current alcohol abuse (regular drinking more than 21 units per week for&#xD;
             males and more than 16 units per week for females [1 unit = 4 cl spirits or&#xD;
             equivalent]).&#xD;
&#xD;
          -  Current use of nicotine containing products more than 5 cigarettes (or equivalent)/day&#xD;
             and/or inability to refrain from the use of nicotine containing products during the&#xD;
             stay at the study centre.&#xD;
&#xD;
          -  Use of caffeine containing beverages more than 600 mg of caffeine/day and/or inability&#xD;
             to refrain from the use of caffeine containing beverages while at the study centre.&#xD;
&#xD;
          -  Blood donation or loss of significant amount of blood within 90 days prior to the&#xD;
             first study treatment administration.&#xD;
&#xD;
          -  Administration of another investigational treatment within 90 days prior to the first&#xD;
             study treatment administration.&#xD;
&#xD;
          -  Unsuitable veins for repeated venipuncture or for cannulation.&#xD;
&#xD;
          -  Predictable poor compliance or inability to communicate well with the study centre&#xD;
             personnel.&#xD;
&#xD;
          -  Inability to participate in all treatment periods.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimmo Ingman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Orion Corporation, Orion Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phase I Unit, Orion Pharma</name>
      <address>
        <city>Espoo</city>
        <zip>02101</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>November 23, 2009</study_first_submitted>
  <study_first_submitted_qc>February 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2010</study_first_posted>
  <last_update_submitted>August 12, 2010</last_update_submitted>
  <last_update_submitted_qc>August 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Irja Korpela, Clinical Study Manager</name_title>
    <organization>Orion Pharma</organization>
  </responsible_party>
  <keyword>Pharmacokinetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
    <mesh_term>Entacapone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

